EARNINGS RELEASE
4Q23 / 2023
LEGAL DISCLOSURE
This presentation may contain certain forward-looking statements and information relating to Alliança Saúde e Participações S.A. (Alliança) and its subsidiaries, which reflect the Company's current views and/or expectations regarding its business performance and future events. Forward-looking statements include, without limitation, any statement that may predict, predict, indicate or imply future results, performance or achievements, and may contain words such as "believes," "anticipates," "expects," "estimates," "could," "predicts," "potential," "likely outcome" or other words or expressions of similar meaning.
Such statements are subject to a number of risks, uncertainties and assumptions. Please be advised that several important factors may cause actual results to differ, any third parties (including investors) are solely and exclusively liable for any investment or business decision or action taken in reliance on the information and statements contained in this presentation or for any consequential, special or similar damages.
Alliança undertakes no obligation to update or revise this presentation in light of new information and/or future events. In addition to the factors identified elsewhere in this presentation, the following factors, among others, could cause actual results to differ materially from forward-looking statements or historical performance: changes in our consumers' financial preferences and conditions and competitive conditions in the markets in which we operate, changes in economic, political and business conditions in Brazil; government interventions, resulting in changes in the Brazilian economy, taxes, tariffs, or regulatory environment, our ability to compete successfully; changes in our business, our ability to successfully implement marketing strategies; our identification of business opportunities, our ability to develop and introduce new products and services, changes in the cost of products and operating costs; our level of indebtedness and other financial obligations, our ability to attract new customers; inflation in Brazil, depreciation of the real against the U.S. dollar and interest rate fluctuations, present or future changes in laws and regulations, and our ability to maintain existing business relationships and create new ones.
2
OPERATIONAL PERFORMANCE AND STRATEGIC POSITIONING
Consecutive growth in 4Q23 and 2023
Revenue and EBITDA grow for another quarter
BRL 1,3 bn
Gross Revenue1 2023
Revenue on the Rise | ||||||
+6% | +8% | |||||
299 | 1,256 | |||||
281 | 1,167 | |||||
4Q22 | 4Q23 | 2022 | 2023 |
- Gross operating income excludes "construction revenue".
BRL 235 mn
Adjusted EBITDA 2023
Highest Historical Evolution of | ||||||
+84% | EBITDA | +29% | ||||
235 | ||||||
47 | ||||||
183 | ||||||
26 |
4Q22 | 4Q23 | 2022 | 2023 |
20%
Adjusted EBITDA Margin 2023
Progression in Profitability in Q4
6.8 p.p. | 3.2 p.p. |
17% | 20% |
17% | |
10% |
4Q22 4Q23 2022 2023
4 | |
Send your questions during the event through the chat, or by WhatsApp: (11) 97781-7295 | |
4Q23 and 2023 Highlights
Productivity
Revenue Growth in Diagnostic Imaging (R$ mi)
7% | 11% | ||
252 | 269 | 1,014 | 1,121 |
Alliances and Expansions
Asset Light Strategies
- Support laboratory of the onco-hematology clinic;
- Outsourcing of anatomical pathology exams;
- Partnership for Exams of Technological Solutions.
Management Agreement and M&A Potential
- Operational partnership with Fonte da Saúde Fund in relation to the units owned by ProEcho with potential for future M&A;
- Execution of an exclusivity agreement for the future acquisition of CEPEM, with expansion in diagnostic services for Women's Health.
4Q22 4Q232022 2023
Commercial Positioning
YoY Average Ticket Variance (%)
MRI | US | CT | CA | |
(Ex-Covid) | ||||
4Q22 vs. 4Q23 | 3.0% | 6.2% | 8.7% | 10.8% |
2022 vs. 2023 | 4.1% | 6.7% | 13.7% | 11.6% |
Organic and Non-Organic Growth
- JV with Unimed Nacional, working to create the first Operational Technical Center in the metropolitan region of Salvador;
- 30-yearconcession (PPP) for the operation of the Regional Urgency and Emergency Hospital of Rondônia.
Incorporation
- Merger of subsidiaries, Delfin Clinic for consolidation and integration of assets into the Company's corporate and operational structures.
5 | |
Send your questions during the event through the chat, or by WhatsApp: (11) 97781-7295 | |
FINANCIAL PERFORMANCE
GROSS REVENUE BREAKDOWN
Evolution of Gross Revenue1 in the period
(BRL mn)
+6% | +8% | |
281 | 299 | 1,256 |
1,167 |
Evolution of Gross Revenue1
(BRL mn)
315 | +6% | |||||
299 | ||||||
283 | 290 | |||||
20% | 281 | |||||
10% | ||||||
% CA 13% | 15% | 11% | ||||
% Imaging 87% | 80% | 85% | 89% | 90% |
4Q22 | 4Q23 | 2022 | 2023 |
4Q19 | 4Q20 | 4Q21 | 4Q22 | 4Q23 |
- Gross operating income excludes "construction revenue".
7 | |
Send your questions during the event through the chat, or by WhatsApp: (11) 97781-7295 | |
GROSS REVENUE BREAKDOWN
Gross Revenue1
(BRL mn)
+8%
Imaging Exams Revenue
(BRL mn) +11%
Variation
(4Q23 vs. 4Q22)
1,167
1,256
1,121
1,014
Resonance Magnetic (MRI)
Share of | Variation | |
Revenue | Average Ticket | |
3% | 36% | +3.0% |
MRI 417
454
Imaging Exams (ex-MRI)
10% | 54% | n/a |
Others 597 667
2022 | 2023 | 2022 | 2023 |
- Gross operating income excludes "construction revenue".
Clinics
Analysis
Total Revenue
1% | 10% | +9.3% |
6% | 100% |
8 | |
Send your questions during the event through the chat, or by WhatsApp: (11) 97781-7295 | |
COSTS AND EXPENSES
% of Adjusted ROL | Non-Recurring | ||||||||||
33% | 35% | ||||||||||
406 | 26% | ||||||||||
21% | 23% | ||||||||||
18 | 20% | ||||||||||
358 | |||||||||||
23 | 13% | ||||||||||
10% | 11% | 10% | 283 | 265 | |||||||
239 | 31 | ||||||||||
229 | 30 | ||||||||||
335 | 388 | ||||||||||
139 | 117 | 118 | 113 | ||||||||
252 | |||||||||||
229 | 239 | 235 | |||||||||
139 | 117 | 118 | 113 | ||||||||
2022 | 2023 | 2022 | 2023 | 2022 | 2023 | 2022 | 2023 | 2022 | 2023 | ||
Personal | Medical Services | Supplies and Support | Depreciation and | 3rd-Party Services | |||||||
1 Others = Maintenance Costs, Occupancy, Long-Term Incentive Program and Others | Labs | Amortization | and Others1 |
9 | |
Send your questions during the event through the chat, or by WhatsApp: (11) 97781-7295 | |
ADJUSTED EBITDA
Positive impact on margin and EBITDA growth higher than in recent years
YoY Variation | Adjusted EBITDA1 in the period |
Fiscal Year Ended
84% | ||||||||
24% | 12% | 25% | ||||||
-20% | ||||||||
-29% | -22% | -43% | ||||||
-58% | ||||||||
51 | 59 | 47 | 63 | 66 | 58 | 47 | ||
32 | ||||||||
26 | ||||||||
4Q21 | 1Q22 | 2Q22 | 3Q22 | 4Q22 | 1Q23 | 2Q23 | 3Q23 | 4Q23 |
1Adjustments ref. to the recovery of investments made by RBD in the public-private partnership with the State of Bahia and to non-recurring expenses.
10 | |
Send your questions during the event through the chat, or by WhatsApp: (11) 97781-7295 | |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Centro de Imagem Diagnósticos SA published this content on 22 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 March 2024 18:46:09 UTC.